Andrea G Kattah1, Maria L G Suarez1, Natasa Milic2, Kejal Kantarci3, Burcu Zeydan3, Thomas Mosley4, Stephen T Turner1, Erin B Ware5,6, Sharon L R Kardia5, Vesna D Garovic1. 1. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. 2. Institute for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 3. Department of Neuroradiology, Mayo Clinic, Rochester, MN. 4. Memory Impairment and Neurodegenerative Dementia Center, University of Mississippi, Jackson, MS. 5. Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI. 6. Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI.
Abstract
OBJECTIVE: Experimental models suggest estrogen has a renoprotective effect, but human studies show variable results. Our objective was to study the association of hormone therapy (HT) and albuminuria in postmenopausal women and to synthesize the results with outcomes from prior studies. METHODS: We analyzed data from postmenopausal women who participated in the second study visit (2000-2004) of the Genetic Epidemiology Network of Arteriopathy (GENOA) study. The exposure was self-reported HT use and the outcome was albuminuria (urine albumin-to-creatinine ratio >25 mg/g creatinine). We also conducted a systematic review and meta-analysis on the association of HT and urine protein in postmenopausal women. Continuous and dichotomous measures of protein excretion were converted to a standardized mean difference (SMD) for each study. RESULTS: In the GENOA cohort (n = 2,217), there were fewer women with albuminuria among HT users than nonusers (9% vs 19%, P < 0.001). HT use was associated with decreased odds of albuminuria (odds ratio 0.65, 95% confidence interval (CI), 0.45-0.95), after adjusting for significant differences in age, race, education, comorbidities, and the age at and cause of menopause. The SMD of the effect of HT on urine proteinuria/albuminuria in the randomized control trials (n = 3) was 0.02 (95% CI, -0.29 to 0.33) and -0.13 (95% CI, -0.31 to 0.05) in the observational studies (n = 9). There was significantly less albuminuria among HT users (SMD -0.15, 95% CI, -0.27 to -0.04) in the 9 studies that only reported albuminuria as an outcome and in the 10 studies with a comparator arm (SMD -0.15, 95% CI, -0.26 to -0.04). CONCLUSIONS: HT is associated with decreased odds of albuminuria, but some of the observed benefits may be related to reported outcomes, the presence of a comparator arm, and the type of study design.
OBJECTIVE: Experimental models suggest estrogen has a renoprotective effect, but human studies show variable results. Our objective was to study the association of hormone therapy (HT) and albuminuria in postmenopausal women and to synthesize the results with outcomes from prior studies. METHODS: We analyzed data from postmenopausal women who participated in the second study visit (2000-2004) of the Genetic Epidemiology Network of Arteriopathy (GENOA) study. The exposure was self-reported HT use and the outcome was albuminuria (urine albumin-to-creatinine ratio >25 mg/g creatinine). We also conducted a systematic review and meta-analysis on the association of HT and urine protein in postmenopausal women. Continuous and dichotomous measures of protein excretion were converted to a standardized mean difference (SMD) for each study. RESULTS: In the GENOA cohort (n = 2,217), there were fewer women with albuminuria among HT users than nonusers (9% vs 19%, P < 0.001). HT use was associated with decreased odds of albuminuria (odds ratio 0.65, 95% confidence interval (CI), 0.45-0.95), after adjusting for significant differences in age, race, education, comorbidities, and the age at and cause of menopause. The SMD of the effect of HT on urine proteinuria/albuminuria in the randomized control trials (n = 3) was 0.02 (95% CI, -0.29 to 0.33) and -0.13 (95% CI, -0.31 to 0.05) in the observational studies (n = 9). There was significantly less albuminuria among HT users (SMD -0.15, 95% CI, -0.27 to -0.04) in the 9 studies that only reported albuminuria as an outcome and in the 10 studies with a comparator arm (SMD -0.15, 95% CI, -0.26 to -0.04). CONCLUSIONS: HT is associated with decreased odds of albuminuria, but some of the observed benefits may be related to reported outcomes, the presence of a comparator arm, and the type of study design.
Authors: Patrick J Manning; Wayne H F Sutherland; Anne R Allum; Sylvia A de Jong; Shirley D Jones Journal: Diabetes Res Clin Pract Date: 2003-04 Impact factor: 5.602
Authors: D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings Journal: Ann Intern Med Date: 1992-12-15 Impact factor: 25.391
Authors: Andrea G Kattah; Carin Y Smith; Liliana Gazzuola Rocca; Brandon R Grossardt; Vesna D Garovic; Walter A Rocca Journal: Clin J Am Soc Nephrol Date: 2018-09-19 Impact factor: 8.237
Authors: Colby J Vorland; Pamela J Lachcik; Elizabeth A Swallow; Corinne E Metzger; Matthew R Allen; Neal X Chen; Sharon M Moe; Kathleen M Hill Gallant Journal: Sci Rep Date: 2019-05-28 Impact factor: 4.379
Authors: Margaret A Zimmerman; Benard O Ogola; Mary M Wilkinson; Bruna Visniauskas; Carmen De Miguel; Jill M Daniel; Sarah H Lindsey Journal: Menopause Date: 2020-12 Impact factor: 3.310